Ionis Pharmaceuticals' 15-minute chart shows MACD, KDJ death crosses.

Ionis Pharmaceuticals' 15-minute chart has recently displayed two significant technical indicators: a MACD Death Cross and a KDJ Death Cross, which occurred on September 19, 2025 at 09:45. These indicators suggest that the stock price is likely to continue its downward trajectory, with a potential for further decline. The momentum behind the stock price is shifting towards the downside, indicating a weakening trend.

Ionis Pharmaceuticals (NASDAQ:IONS) has recently experienced a notable technical shift in its stock price, as evidenced by two significant indicators: a MACD Death Cross and a KDJ Death Cross. These indicators, which occurred on September 19, 2025, at 09:45, suggest a potential downward trend in the stock's price. This shift in momentum is a signal that the stock price may continue to decline, indicating a weakening trend for investors to consider.

Despite these technical indicators, Ionis Pharmaceuticals reported strong earnings for the last quarter, with earnings per share (EPS) of $0.70, significantly exceeding analysts' expectations of $0.19. The company's revenue doubled year-over-year to $452 million, demonstrating robust financial performance. However, the negative net margin of 28.25% and a negative return on equity of 45.29% highlight the challenges in profitability that the company continues to face.

Analysts have responded to the recent earnings report with mixed sentiments. HC Wainwright boosted their target price on shares of Ionis Pharmaceuticals from $70.00 to $95.00 and gave the stock a "buy" rating. Meanwhile, Goldman Sachs Group maintained a "sell" rating with a price objective of $45.00. Citigroup and Jefferies Financial Group both increased their price targets, with Citigroup setting a target of $84.00 and Jefferies Financial Group setting a target of $96.00, both with "buy" ratings.

Institutional investors and hedge funds have also shown interest in Ionis Pharmaceuticals. GAMMA Investing LLC boosted its position by 3,786.5% in the first quarter, while Fifth Third Bancorp, Raymond James Financial Inc., American Century Companies Inc., and Edmond DE Rothschild Holding S.A. also increased their stakes. These investments highlight the continued belief in the company's potential despite the recent technical indicators.

Investors should monitor the stock closely for any further developments in the technical indicators and earnings reports. The company's pipeline of RNA-targeted therapeutics, including SPINRAZA, QALSODY, WAINUA, TEGSEDI, and WAYLIVRA, holds promise for future growth. However, the current technical signals suggest a cautious approach for investors in the near term.